Product Datasheet

Lunresertib

Catalog No. **BP-02042** · CAS **2719793-90-3** · Form **free base** · Physical state **solid** · Color **Off-white to gray** · Version **1.0** · Revision **2026-09-11**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
Wee1	**Cancer**

Molecular formula	$C_{18}H_{20}N_4O_2$
Molecular weight	**324.3770**

STRUCTURE



DESCRIPTION

RP-6306 is a Protein Kinase, Membrane Associated Tyrosine/Threonine 1 (PKMYT1) inhibitor, which can be used for the research of cancer.

BIOLOGICAL ACTIVITY

In Vitro

lunresertib (500 nM; for 24 h) treatment induces pan-γH2AX in an HCC1569 breast cancer cell line, indicating that tumour-derived CCNE1 amplification also renders cells vulnerable to DNA damage induction following PKMYT1 inhibition.

lunresertib treatment causes unscheduled activation of CDK1 selectively in CCNE1-overexpressing cells, promoting early mitosis in cells undergoing DNA synthesis.

In Vivo

lunresertib (15, 50, and 300 ppm; oral; daily; for 21 days) results in a statistically significant and dose-dependent reduction in OVCAR3 tumor growth in CCNE1-amplified ovarian xenograft model (OVCAR3).

SOLUBILITY

Soluble in DMSO 50 mg/mL

REFERENCES

[1]. Szychowski J, et al. Compounds, pharmaceutical compositions, and methods of preparing compounds and their use. WO2021195781A1.

[2]. David Gallo, et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604(7907):749-756.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com